List of works - Pierre Grammond

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

scientific article published on 9 August 2017

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

scientific article published on 01 November 2018

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

scientific article published on 01 January 2019

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

scientific article

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

scientific article published on 5 December 2014

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

scientific article published on April 2016

Comparative efficacy of switching to natalizumab in active multiple sclerosis

scientific article

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

scientific article published on 13 January 2019

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

scientific article published on April 2015

Contribution of different relapse phenotypes to disability in multiple sclerosis.

scientific article published on 7 April 2016

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

scientific article

Defining reliable disability outcomes in multiple sclerosis

scientific article published on 10 September 2015

Defining secondary progressive multiple sclerosis

scientific article published on 7 July 2016

Geographical variations in sex ratio trends over time in multiple sclerosis.

scientific article

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

scientific article published on 3 November 2016

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

scientific article published on 28 September 2016

Increasing age at disability milestones among MS patients in the MSBase Registry

scientific article published on 14 April 2012

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

scientific article published on April 2017

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

scientific article

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

scientific article

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

scientific article

Predictors of disability worsening in clinically isolated syndrome.

scientific article published on 27 March 2015

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

scientific article published on 4 May 2016

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

scientific article published on 24 November 2016

Risk of relapse phenotype recurrence in multiple sclerosis.

scientific article

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

scientific article published on 20 October 2014

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

scientific article published on 18 October 2013

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

scientific article published on 17 January 2015

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

scientific article published on 21 July 2015

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

scientific article published in September 2017

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

scientific article published on 10 February 2017

List of works by Pierre Grammond

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Comparative efficacy of switching to natalizumab in active multiple sclerosis

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

Contribution of different relapse phenotypes to disability in multiple sclerosis.

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

Defining reliable disability outcomes in multiple sclerosis

Defining secondary progressive multiple sclerosis

Geographical variations in sex ratio trends over time in multiple sclerosis.

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

Increasing age at disability milestones among MS patients in the MSBase Registry

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry

Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

Predictors and dynamics of postpartum relapses in women with multiple sclerosis.

Predictors of disability worsening in clinically isolated syndrome.

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

Risk of relapse phenotype recurrence in multiple sclerosis.

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.